Experienced investors (as some here claim they are) shouldn't become locked into expectations of milestone dates in the very speculative biotech industry.

I swear, some folks must go through their days looking for reasons to be unhappy about something. That seems to be their main focus regarding this investment.

LymPro is weeks away from commercialization and generating revenue. We'll soon be learning about a spinoff or sale of the diagnostic division or LymPro in the next few weeks or months. Our CEO has clearly stated shareholders will be rewarded in this transaction and that this is a key consideration for doing it. Yet some want to nickel-and-dime the company to death over slipped milestone dates, as though that has some major impact on what's unfolding here.